首页> 外文期刊>Leukemia Research Reports >A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia
【24h】

A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia

机译:慢性粒细胞性白血病进展后获得e6a2 BCR-ABL融合转录本的急性粒细胞白血病一例

获取原文
           

摘要

Philadelphia (Ph) chromosome is a cytogenetic hallmark of chronic myeloid leukemia (CML). Most patients with CML harbor either the e13a2 or e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts. We report a patient with chronic myelomonocytic leukemia (CMML), initially Ph chromosome negative at presentation, with rapid disease progression to acute myeloid leukemia (AML) and appearance of Ph chromosome and BCR-ABL e6a2, a very uncommon fusion transcript. The AML was refractory to treatment with subsequent emergence and dominance of a Ph negative leukemic clone. The patient expired shortly after disease progression.
机译:费城(Ph)染色体是慢性粒细胞白血病(CML)的细胞遗传学标志。大多数CML患者携带e13a2或e14a2 BCR-ABL融合产物,而一小部分病例表达e1a2或e19a2转录本。我们报道了一名慢性粒细胞单核细胞白血病(CMML)患者,最初呈Ph染色体阴性,疾病迅速发展为急性髓细胞白血病(AML),并出现了Ph染色体和BCR-ABL e6a2(一种非常罕见的融合转录本)。 AML难以治疗,随后出现Ph阴性白血病克隆并占据主导地位。患者在疾病进展后不久就死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号